Cumberland Pharmaceuticals Inc.
CPIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $8,292 | $10,837 | $11,713 | $10,436 |
| % Growth | -23.5% | -7.5% | 12.2% | – |
| Cost of Goods Sold | $989 | $2,011 | $1,426 | $1,976 |
| Gross Profit | $7,304 | $8,826 | $10,287 | $8,459 |
| % Margin | 88.1% | 81.4% | 87.8% | 81.1% |
| R&D Expenses | $1,253 | $1,468 | $1,295 | $1,293 |
| G&A Expenses | $2,572 | $2,875 | $2,463 | $3,326 |
| SG&A Expenses | $7,006 | $7,099 | $6,695 | $7,549 |
| Sales & Mktg Exp. | $4,434 | $4,224 | $4,232 | $4,223 |
| Other Operating Expenses | $1,010 | $1,006 | $1,005 | $1,459 |
| Operating Expenses | $9,269 | $9,573 | $8,995 | $10,301 |
| Operating Income | -$1,965 | -$747 | $1,292 | -$1,842 |
| % Margin | -23.7% | -6.9% | 11% | -17.7% |
| Other Income/Exp. Net | $22 | $18 | -$38 | -$117 |
| Pre-Tax Income | -$1,943 | -$730 | $1,254 | -$1,959 |
| Tax Expense | $6 | $6 | $6 | -$57 |
| Net Income | -$1,941 | -$741 | $1,257 | -$1,904 |
| % Margin | -23.4% | -6.8% | 10.7% | -18.2% |
| EPS | -0.13 | -0.05 | 0.08 | -0.14 |
| % Growth | -160% | -162.5% | 157.1% | – |
| EPS Diluted | -0.13 | -0.05 | 0.08 | -0.14 |
| Weighted Avg Shares Out | 14,954 | 14,961 | 14,943 | 13,971 |
| Weighted Avg Shares Out Dil | 14,954 | 14,961 | 15,260 | 13,971 |
| Supplemental Information | – | – | – | – |
| Interest Income | $132 | $127 | $126 | $107 |
| Interest Expense | $110 | $110 | $164 | $223 |
| Depreciation & Amortization | $1,038 | $1,319 | $1,317 | $1,782 |
| EBITDA | -$796 | $699 | $2,734 | $46 |
| % Margin | -9.6% | 6.5% | 23.3% | 0.4% |